A case of impaired consciousness due to fentanyl sublingual tablet overdose
Palliative Care Research
; : 527-530, 2015.
Article
in Japanese
| WPRIM (Western Pacific)
| ID: wpr-376664
Responsible library:
WPRO
ABSTRACT
Oral transmucosal fentanyl has been developed for the management of breakthrough pain in cancer patients. Buccal and sublingual fentanyl tablets have been licensed in Japan. However, the optimal use of oral transmucosal fentanyl has not been elucidated. We describe the treatment of cancer‒related pain using a 100μg fentanyl sublingual tablet and a 12.5μg/hr fentanyl patch in a 77 year‒old man with rectal cancer and thoracic vertebral metastasis. After the first use of the fentanyl sublingual tablet, the patient’s consciousness was impaired for 6 hours, however respiration was stable. This case shows that administration of fentanyl sublingual tablets may not be recommended for breakthrough pain incancer patients who are being treated with 30mg/day of oral morphine equivalent dose (20mg/day oxycodone, 12.5μg/hr fentanyl patch).
Search on Google
Database:
WPRIM (Western Pacific)
Language:
Japanese
Journal:
Palliative Care Research
Year:
2015
Document type:
Article